Sprout Capital VII Healthcare Technology Portfolio Investment Summary (as of March 31, 2014)

Summary

Sprout Capital VII Healthcare Technology Portfolio Investment Summary (as of March 31, 2014) The document is a routine private‑equity portfolio performance table showing investment amounts, returns, and IRRs for various healthcare‑technology companies. It contains no direct references to high‑profile individuals, government actions, or suspicious financial flows, limiting its investigative value. However, the list of portfolio companies could be a modest lead for tracing later corporate events or potential conflicts of interest if any of the firms later interact with public policy or government contracts. Key insights: Provides vintage year, cost, realized and unrealized values for 17 portfolio companies.; Overall fund IRR of 10.1% with a gross multiple of 1.74.; Notable high‑performing investments include Cephalon (293.2% return) and Charles River Laboratories (121.6% return).